These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
137 related articles for article (PubMed ID: 39276585)
1. Overview of the PRMT6 modulators in cancer treatment: Current progress and emerged opportunity. Peng J; Ni B; Li D; Cheng B; Yang R Eur J Med Chem; 2024 Dec; 279():116857. PubMed ID: 39276585 [TBL] [Abstract][Full Text] [Related]
2. Overview of PRMT1 modulators: Inhibitors and degraders. Wu J; Li D; Wang L Eur J Med Chem; 2024 Dec; 279():116887. PubMed ID: 39316844 [TBL] [Abstract][Full Text] [Related]
3. Discovery of a first-in-class degrader for the protein arginine methyltransferase 6 (PRMT6). Yang H; Zhang Q; Zhou S; Hu Z; Tang Q; Li Z; Feng Q; Yu L Bioorg Chem; 2024 Jul; 148():107439. PubMed ID: 38754310 [TBL] [Abstract][Full Text] [Related]
4. Discovery of a First-in-Class Protein Arginine Methyltransferase 6 (PRMT6) Covalent Inhibitor. Shen Y; Li F; Szewczyk MM; Halabelian L; Park KS; Chau I; Dong A; Zeng H; Chen H; Meng F; Barsyte-Lovejoy D; Arrowsmith CH; Brown PJ; Liu J; Vedadi M; Jin J J Med Chem; 2020 May; 63(10):5477-5487. PubMed ID: 32367723 [TBL] [Abstract][Full Text] [Related]
5. The Emerging Role of PRMT6 in Cancer. Chen Z; Gan J; Wei Z; Zhang M; Du Y; Xu C; Zhao H Front Oncol; 2022; 12():841381. PubMed ID: 35311114 [TBL] [Abstract][Full Text] [Related]
6. Overview of class I HDAC modulators: Inhibitors and degraders. Huang Z; Zeng L; Cheng B; Li D Eur J Med Chem; 2024 Oct; 276():116696. PubMed ID: 39094429 [TBL] [Abstract][Full Text] [Related]
7. Discovery of a Potent, Selective, and Cell-Active Dual Inhibitor of Protein Arginine Methyltransferase 4 and Protein Arginine Methyltransferase 6. Shen Y; Szewczyk MM; Eram MS; Smil D; Kaniskan HÜ; de Freitas RF; Senisterra G; Li F; Schapira M; Brown PJ; Arrowsmith CH; Barsyte-Lovejoy D; Liu J; Vedadi M; Jin J J Med Chem; 2016 Oct; 59(19):9124-9139. PubMed ID: 27584694 [TBL] [Abstract][Full Text] [Related]
8. A First-in-Class, Highly Selective and Cell-Active Allosteric Inhibitor of Protein Arginine Methyltransferase 6. Shen Y; Li F; Szewczyk MM; Halabelian L; Chau I; Eram MS; Dela Seña C; Park KS; Meng F; Chen H; Zeng H; Dong A; Wu H; Trush VV; McLeod D; Zepeda-Velázquez CA; Campbell RM; Mader MM; Watson BM; Schapira M; Arrowsmith CH; Al-Awar R; Barsyte-Lovejoy D; Kaniskan HÜ; Brown PJ; Vedadi M; Jin J J Med Chem; 2021 Apr; 64(7):3697-3706. PubMed ID: 33591753 [TBL] [Abstract][Full Text] [Related]
10. Protein arginine methyltransferase 6-dependent gene expression and splicing: association with breast cancer outcomes. Dowhan DH; Harrison MJ; Eriksson NA; Bailey P; Pearen MA; Fuller PJ; Funder JW; Simpson ER; Leedman PJ; Tilley WD; Brown MA; Clarke CL; Muscat GE Endocr Relat Cancer; 2012 Aug; 19(4):509-26. PubMed ID: 22673335 [TBL] [Abstract][Full Text] [Related]
11. Small molecules targeting HDAC6 for cancer treatment: Current progress and novel strategies. Huang Z; Li L; Cheng B; Li D Biomed Pharmacother; 2024 Sep; 178():117218. PubMed ID: 39084081 [TBL] [Abstract][Full Text] [Related]
12. Rational Design and Synthesis of Selective PRMT4 Inhibitors: A New Chemotype for Development of Cancer Therapeutics*. Sutherland M; Li A; Kaghad A; Panagopoulos D; Li F; Szewczyk M; Smil D; Scholten C; Bouché L; Stellfeld T; Arrowsmith CH; Barsyte D; Vedadi M; Hartung IV; Steuber H; Britton R; Santhakumar V ChemMedChem; 2021 Apr; 16(7):1116-1125. PubMed ID: 33513288 [TBL] [Abstract][Full Text] [Related]
13. Protein arginine methyltransferases: promising targets for cancer therapy. Hwang JW; Cho Y; Bae GU; Kim SN; Kim YK Exp Mol Med; 2021 May; 53(5):788-808. PubMed ID: 34006904 [TBL] [Abstract][Full Text] [Related]
14. Targeting protein arginine methyltransferase 5 in cancers: Roles, inhibitors and mechanisms. Chen Y; Shao X; Zhao X; Ji Y; Liu X; Li P; Zhang M; Wang Q Biomed Pharmacother; 2021 Dec; 144():112252. PubMed ID: 34619493 [TBL] [Abstract][Full Text] [Related]
15. Inhibition of protein arginine methyltransferase 6 activates interferon signaling and induces the apoptosis of endometrial cancer cells via histone modification. Inoue F; Sone K; Kumegawa K; Hachijo R; Suzuki E; Tanimoto S; Tsuboyama N; Kato K; Toyohara Y; Takahashi Y; Kusakabe M; Kukita A; Honjoh H; Nishijima A; Taguchi A; Miyamoto Y; Tanikawa M; Iriyama T; Mori M; Wada-Hiraike O; Oda K; Suzuki H; Maruyama R; Osuga Y Int J Oncol; 2024 Mar; 64(3):. PubMed ID: 38299254 [TBL] [Abstract][Full Text] [Related]
16. Epigenetic small molecule modulators of histone and DNA methylation. Hauser AT; Robaa D; Jung M Curr Opin Chem Biol; 2018 Aug; 45():73-85. PubMed ID: 29579619 [TBL] [Abstract][Full Text] [Related]
17. Cell cycle regulation by the PRMT6 arginine methyltransferase through repression of cyclin-dependent kinase inhibitors. Kleinschmidt MA; de Graaf P; van Teeffelen HA; Timmers HT PLoS One; 2012; 7(8):e41446. PubMed ID: 22916108 [TBL] [Abstract][Full Text] [Related]
18. Discovery of a Potent Class I Protein Arginine Methyltransferase Fragment Inhibitor. Ferreira de Freitas R; Eram MS; Szewczyk MM; Steuber H; Smil D; Wu H; Li F; Senisterra G; Dong A; Brown PJ; Hitchcock M; Moosmayer D; Stegmann CM; Egner U; Arrowsmith C; Barsyte-Lovejoy D; Vedadi M; Schapira M J Med Chem; 2016 Feb; 59(3):1176-83. PubMed ID: 26824386 [TBL] [Abstract][Full Text] [Related]
19. PELP1 oncogenic functions involve alternative splicing via PRMT6. Mann M; Zou Y; Chen Y; Brann D; Vadlamudi R Mol Oncol; 2014 Mar; 8(2):389-400. PubMed ID: 24447537 [TBL] [Abstract][Full Text] [Related]
20. Recent advances in targeting protein arginine methyltransferase enzymes in cancer therapy. Smith E; Zhou W; Shindiapina P; Sif S; Li C; Baiocchi RA Expert Opin Ther Targets; 2018 Jun; 22(6):527-545. PubMed ID: 29781349 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]